Drugs Made In America Acquisition II Corp. Ordinary Shares (DMII)
StalwartFairStock Score: 16/100 — RISKY
Key Financials
| Current Price | $10.03 |
| Market Cap | $638M |
| P/E Ratio | 71.64 |
| ROE | —% |
| Dividend Yield | —% |
| Sector | Financial Services |
Strengths
- Altman Z-Score of 21.4 confirms minimal bankruptcy risk and strong solvency
Concerns
- Trades significantly above Graham Number ($5) with negative 97% margin of safety—limited downside protection
- Weak Piotroski F-Score of 1/9 suggests deteriorating financial quality across multiple dimensions
AI Analysis
Drugs Made In America Acquisition II Corp. Ordinary Shares is a micro-cap financial services company valued at $638 million. From a quality standpoint, Drugs shows weak Piotroski F-Score of 1/9 signaling deteriorating fundamentals and Altman Z-Score of 21.4 confirms fortress-level solvency. On valuation, the stock is commanding a steep 66.9x multiple, with trades above its Graham Number with a negative 97% margin. Our composite FairStock Score of 16/100 reflects below-average fundamentals overall. Investors should weigh the business quality against the current price and their own margin of safety requirements.
Bull Case
Improving fundamentals and sector tailwinds could drive meaningful earnings growth, compressing the effective multiple for patient investors. Operational leverage in the business model means incremental revenue growth could disproportionately boost bottom-line profitability.
Bear Case
At 67x earnings, any growth disappointment triggers rapid multiple compression—a 20% earnings miss plus multiple contraction to 20x implies 40%+ downside. Regulatory changes, input cost inflation, or demand normalization represent underappreciated risks that could materially impact forward estimates.
Data from SEC filings. AI analysis is for educational purposes only — not investment advice. Scoring methodology · Disclaimer